Follow-up: The Medicines Co. upgraded at JPMorgan

theflyonthewall.com

As previously reported, JPMorgan upgraded The Medicines Co. to Overweight from Neutral. The firm upgraded shares following the positive top-line Ph III results for the oritavancin SOLO-1 trial and views risk/reward as attractive. Price target raised to $32 from $28.

Rates

View Comments (0)